Appendix 4C: Quarterly Cash Flow Report
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: PR Newswire
MELBOURNE, Australia, Oct. 31, 2019 /PRNewswire/ -- Benitec Biopharma (ASX: BLT) (NASDAQ: BNTC) ("Benitec" or the "Company"), a biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced its Appendix 4C for the quarter ending 30 September 2019. Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma, commented on today's news, "The recent capital raise solidified our strong financial position and broadened our institutional investor base. We continue to work diligently to advance our primary ddRNAi product candidate, BB-301, while actively seeking strategic partnerships to support the advancement of BB-103 and the Hepatitis B Virus-focused research and development program."In September 2019, in conjunction with Ladenburg Thalmann, Benitec completed a Registered Direct Offering yielding A$3.22 million of gross proceeds.
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update [Yahoo! Finance]Yahoo! Finance
- Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceGlobeNewswire
- Benitec Biopharma Inc. (NASDAQ: BNTC) had its "overweight" rating re-affirmed by analysts at Piper Sandler.MarketBeat
- Benitec Biopharma: OPMD Program Continues To Advance With Catalysts [Seeking Alpha]Seeking Alpha
BNTC
Sec Filings
- 11/21/24 - Form 4
- 11/18/24 - Form SC
- 11/14/24 - Form SCHEDULE
- BNTC's page on the SEC website